Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

SmofKabiven

Phase 3Small molecule

JJW Life Science

1

Indications

2

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

LaparotomyActive, not recruiting

LaparotomyPhase 3

Active, not recruiting

Timeline

Expected Milestones

Q4 2026

ApprovedActive, not recruiting

Laparotomy

NCT06089551

Clinical

Trials by Indication[1]

Parenteral Nutrition1 trial

A Safety, Efficacy Study of CombiflexOmega Versus SmofKabiven in Patients With Parenteral Nutrition

Completed·JJW Life Science·Phase 3·NCT01533766·50 enrolled

Laparotomy1 trial

Early Versus Postponed Supplementary Parenteral Nutrition After Major Emergency Abdominal Surgery: A Randomized, Controlled Multicenter Trial

Active, not recruiting·CCopenhagen University Hospital at Herlev·Approved·NCT06089551·342 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for SmofKabiven. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SmofKabiven compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SmofKabiven. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — JW Life Science company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: JJW Life Science

Related News